Publications

5808 Results

Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831

Authors
A Moreno-Aspitia;DW Hillman;SH Dyar;KS Tenner;J Gralow;P Kaufman;NE Davidson;JM Lafky;M Reinholz;WL Likngle;LA Kutteh;WP Carney;AC Dueck;AE Perez
Journal / Conference
Cancer 119(15):2675-2682
Year
2013
Research Committee(s)
Breast
PMID
PMID23744760
PMC
PMC4126833
Study Number(s)
N9831

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial

Authors
A Perez;A Dueck;A McCullough;B Chen;X Geiger;R Jenkins;W Lingle;N Davidson;S Martino;P Kaufman;LA Kutteh;G Sledge;L Harris;J Gralow;M Reinholz
Journal / Conference
Journal of Clinical Oncology 31(17):2115-2122
Year
2013
Research Committee(s)
Breast
PMID
PMID23650412
PMC
PMC3731983
Study Number(s)
N9831

The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome

Authors
AJ Vickers;DD Sjoberg;DP Ankerst;CM Tangen;P Goodman;IM Thompson
Journal / Conference
Cancer 119(16):3007-3011
Year
2013
Research Committee(s)
Cancer Control
PMID
PMID23720006
PMC
PMC3735626
Study Number(s)
SWOG-9217

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor ACOSOG Z9000 (Alliance) intergroup phase 2 trial

Authors
R Dematteo;K Ballman;C Antonescu;C Corless;V Kolesnikova;M Von Mehren;M McCarter;J Norton;R Maki;P Pisters;G Demetri;M Brennan;K Owzar
Journal / Conference
Annals of Surgery 258(3):422-429;
Year
2013
Research Committee(s)
Sarcoma
PMID
PMID23860199
PMC
pending
Study Number(s)
CTSU/Z9000

The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database

Authors
W Cheung;Q Shi;M O'Connell;J Cassidy;CD Blanke;DJ Kerr;J Meyers;E Van Cutsem;SR Alberts;G Yothers;D Sargent
Journal / Conference
Clinical Colorectal Cancer 12(3):179-187
Year
2013
Research Committee(s)
Cancer Survivorship and Gastrointestinal
PMID
PMID23810482
PMC
PMC3760214
Study Number(s)
SWOG-9415 (INT-0153) (CALGB-9498) (ECOG-S9415) (NCCTG-S9415)

All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129

Authors
D Douera;L Zickl;C Schiffer;F Appelbaum;J Feusnere;L Shepherd;C Willman;C Bloomfield;E Paietta;R Gallagher;J Park;J Rowe;P Wiernik;M Tallman
Journal / Conference
Leukemia Research 37(7):795-801
Year
2013
Research Committee(s)
Leukemia
PMID
PMID23528262
PMC
PMC4174301

Prostate cancer prevention: strategies for agent development [Review]

Authors
H Parnes;MG House;JA Tanagrea
Journal / Conference
Current Opinion in Oncology 25(3):242-251
Year
2013
Research Committee(s)
Cancer Control, Genitourinary, Prevention, Screening, and and Surveillance
PMID
PMID23518594
PMC
n/a - review article
Study Number(s)
S0000, SWOG-9217, S9917

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: trial design and current status

Authors
T Andre;T Iveson;R Labianca;JA Meyerhardt;I Souglakos;T Yoshino;J Paul;A Sobrero;J Taieb;A Shields;A Ohtsu;A Grothey;DJ Sargent
Journal / Conference
Current Colorectal Cancer Reports 9:261-269
Year
2013
Research Committee(s)
Gastrointestinal
PMID
PMID24032000
PMC
PMC3766516
Study Number(s)
CTSU/C80702

Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: findings from CALGB 89803/Alliance

Authors
J Jeon;K Sato;D Niedzwiecki;X Ye;LB Saltz;RJ Mayer;RB Mowat;R Whittom;H Hantel;A Benson;D Wigler;D Atienza;M Messino;H Kindler;A Venook;C Fuchs;J Meyerhardt
Journal / Conference
Clinical Colorectal Cancer 12(4):233-238;
Year
2013
Research Committee(s)
Gastrointestinal
PMID
PMID24035029
PMC
PMC3818492
Study Number(s)
C89803

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

Authors
GD Goss;C O'Callaghan;I Lorimer;MS Tsao;GA Masters;J Jett;MJ Edelman;R Lilenbaum;AH Choy;F Khuri;K Pisters;D Gandara;K Kernstine;C Butts;J Noble;TA Hensing;K Rowland;J Schiller;K Ding;FA Shepherd
Journal / Conference
Journal of Clinical Oncology 31(27):3320-3326;
Year
2013
Research Committee(s)
Lung
PMID
PMID23980091
PMC
PMC3770864